Premium
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
Author(s) -
Jabbour Elias,
GarciaManero Guillermo,
Batty Nicolas,
Shan Jenny,
O'Brien Susan,
Cortes Jorge,
Ravandi Farhad,
Issa JeanPierre,
Kantarjian Hagop
Publication year - 2010
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.25247
Subject(s) - decitabine , medicine , chronic myelomonocytic leukemia , myelodysplastic syndromes , international prognostic scoring system , disease , leukemia , azacitidine , oncology , surgery , bone marrow , biochemistry , gene expression , chemistry , dna methylation , gene
BACKGROUND: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. METHODS: Data from 87 patients with MDS (n = 67) and chronic myelomonocytic leukemia (n = .20) after failure of decitabine regimens were reviewed. RESULTS: After a median follow‐up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12‐month survival rate was 28%. The estimated 12‐month survival rates were 27%, 33%, and 33%, respectively, for patients with high‐risk, intermediate‐2‐risk, and intermediate‐1‐risk disease ( P = .99) by the International Prognostic Scoring System. The estimated 12‐month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low‐risk, intermediate‐1‐risk, intermediate‐2‐risk, and high‐risk disease according to The University of Texas M. D. Anderson Cancer Center risk model ( P = .01). CONCLUSIONS: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure. Cancer 2010. © 2010 American Cancer Society.